drugset / Trial / NCT00940381

Sirolimus and Cetuximab in Advanced Malignancies

NCT00940381

Phase 1 Completed 165 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of sirolimus and cetuximab that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Timeline

Start
2009-07
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 65 mg/m2 Intravenous
Subject Sirolimus Small molecule 1 mg Oral